Skip to content
PeptideWiki.bio

Recovery

KLOW

Also called GHK-Cu + BPC-157 + TB-500 + KPV

InjectableEvidence DEvery day
Half-life
variesby component
Typical vial
80mg
Research amounts
2–3mg

per administration

Common schedule
Every day
From community reports

The amounts going around come from sellers and forums, not from any study.

Quick start

KLOW at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.

Typical dose
2–3 mg per administration
How often
Every day
Where
Commonly subcutaneous Sites and rotation
Storage
Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details

A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.

Work out your draw

These numbers are a starting point — change any of them.

Vial label

Copy this into your label printer.

What one draw delivers

Per-draw amounts for the KLOW blend
ComponentSharePer draw
GHK-Cu63%1.25 mg
BPC-15713%250 mcg
TB-50013%250 mcg
KPV13%250 mcg

Every draw has these same proportions.

23 mg of KLOW per administration, worked out from the components rather than quoted from a study of the blend.

A fixed-ratio blend sold as one vial, so it is drawn as a whole. The range here is worked out from the components rather than quoted from a study of the blend: it is sized to keep GHK-Cu, which is 63% of the vial, inside its own range, which also lands BPC-157 and KPV inside theirs. TB-500 comes out well below its standalone range at any draw that does so — at 13% of the vial the ratio cannot satisfy both. Its components are covered on their own pages, and no combined human schedule is established, so no schedule table is shown.

What is in a 80 mg KLOW vial

Vial contents for the KLOW blend
ComponentSharePer vial
GHK-Cu63%50 mg
BPC-15713%10 mg
TB-50013%10 mg
KPV13%10 mg

Every draw has these same proportions.

What it can be combined with

How KLOW is commonly discussed alongside other peptides and drugs.

Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.

  • BPC-157KLOW already contains BPC-157, so adding standalone BPC-157 doubles that component — account for the blend's share first.
    Use caution
  • GHK-CuKLOW already contains GHK-Cu (63% of the vial), so a standalone vial stacks on the blend's share.
    Use caution
  • KPVKLOW already contains KPV, so a standalone vial stacks on the blend's share.
    Use caution
  • TB-500KLOW already contains TB-500, so a standalone vial stacks on the blend's share.
    Use caution

Modelled level — every day

One curve per component: the components clear at very different rates.

GHK-Cu (in KLOW)BPC-157 (in KLOW)TB-500 (in KLOW)KPV (in KLOW)

Where these numbers come from

  • Component literatureNo study exists of the blend itself; see the BPC-157, TB-500, GHK-Cu and KPV pages for the components' sources.

Next steps

Others in recovery